La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Revelation Biosciences a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Revelation Biosciences..

Revelation Biosciences (NASDAQ:REVBW) Azioni, Catena delle Opzioni

Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

Revelation Biosciences Inc

WIIM

FTNT

Fortinet shares are trading lower. The company reported Q3 financial results.

Natures Sunshine Products (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NATR#NASDAQ">NATR</a>) raises FY2024 sales outlook from $436.00 million-445.00 million to $443.00 million-448.00 million.

News

Guidance

NATR

Natures Sunshine Products Raises FY2024 Sales Guidance from $436.00M-445.00M to $443.00M-448.00M  VS Est. $439.16M

Orion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OEC#NYSE">OEC</a>) reported quarterly earnings of $0.47 per share which met the analyst consensus estimate. The company reported quarterly sales of $463.400 million which missed the analyst consensus estimate of $480.665 million by 3.59 percent. This is a 0.60 percent decrease over sales of $466.200 million the same period last year.

Earnings

Earnings Misses

Orion Q3 2024 Adj. EPS $0.47, Inline, Sales $463.400M Miss $480.665M Estimate

ANET

Arista Networks shares are trading lower. The company reported Q3 financial results.

Atea Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVIR#NASDAQ">AVIR</a>) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.49) by 24.49 percent. This is a 7.5 percent increase over losses of $(0.40) per share from the same period last year.

Earnings Beats

AVIR

Atea Pharmaceuticals Q3 2024 GAAP EPS $(0.37) Beats $(0.49) Estimate

MNST

Monster Beverage shares are trading lower after the company reported worse-than-expected Q3 financial results.

HCI Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCI#NYSE">HCI</a>) reported quarterly earnings of $0.47 per share which beat the analyst consensus estimate of $0.27 by 74.07 percent. The company reported quarterly sales of $175.317 million which missed the analyst consensus estimate of $190.503 million by 7.97 percent. This is a 33.18 percent increase over sales of $131.644 million the same period last year.

HCI Group Q3 2024 Adj. EPS $0.47 Beats $0.27 Estimate, Sales $175.317M Miss $190.503M Estimate

Logan Ridge Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRFC#NASDAQ">LRFC</a>) reported quarterly earnings of $0.37 per share which beat the analyst consensus estimate of $0.36 by 2.78 percent. The company reported quarterly sales of $5.148 million which beat the analyst consensus estimate of $5.100 million by 0.94 percent. This is a 0.27 percent decrease over sales of $5.162 million the same period last year.

LRFC

Logan Ridge Finance Q3 2024 GAAP EPS $0.37 Beats $0.36 Estimate, Sales $5.148M Beat $5.100M Estimate

Motorola Solutions shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY24 adjusted EPS guidance above estimates.

In a pioneering study funded by the UK Government, researchers at Imperial College London are set to examine the potential of <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psilocybin-assisted therapy</a> to treat <a href="https://www.benzinga.com/topic/opioid-crisis">opioid addiction</a>. As Leafie <a href="https://www.leafie.co.uk/news/psilocybin-opioid-treatment-uk-study/">reported</a>, this marks the first time that the UK government has backed research into using <a href="https://www.benzinga.com/topic/psilocybin">psilocybin</a> for substance addiction, a critical step in broadening the therapeutic tools available for opioid dependency.
<h3 class="wp-block-heading">Traditional Treatments Fall Short Amid High Relapse Rates</h3>
The UK, with some of the <a href="https://www.benzinga.com/topic/opioid-crisis">highest opioid use rates</a> globally, faces relapse rates near 90% within a year despite treatments like methadone and talk therapies "Finding new and effective treatments is essential," stated Dr. David Erritzoe, Clinical Director at Imperial's Centre for Psychedelic Research. "If this trial is successful, it offers hope for a new type of treatment that could make a significant difference to this group of people."
<h3 class="wp-block-heading">Psilocybin And Talk Therapy Combined</h3>
The study will involve participants recovering from heroin and other opioids, including those on replacement therapies like methadone. Over six months, participants will receive psilocybin doses and therapy, with MRI scans tracking brain response. Dr. Louise Paterson from Imperial's Centre for Psychedelic Research noted, "This trial will examine whether we can improve recovery in a severely under-served group of people… We want to see if it works equally well for opioid use disorder."
<h3 class="wp-block-heading">A Collaborative Effort To Reduce Drug-Related Deaths In The UK</h3>
Funded by the National Institute for Health and Care Research under the Addiction Healthcare Goals program, the study is one of four initiatives aimed at reducing drug-related deaths. Professor Anne Lingford-Hughes, chair of the program, emphasized the urgency of innovation in addiction treatment, saying, "The Addiction Healthcare Goals program is pleased to fund promising innovations that have brought together partnerships between industry, academia and treatment organizations."
Recruitment for participants is slated to begin by spring 2025. If successful, this study could pave the way for psilocybin-assisted therapy as a revolutionary approach in treating opioid addiction.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/11/41829368/overdose-crisis-in-shadows-of-elections-as-black-indigenous-americans-deaths-rise">Overdose Crisis In Shadows Of Elections As Black, Indigenous Americans Deaths Rise</a></li>
</ul>
Cover image made with AI

Cannabis

Government

Psychedelics

Eurozone

UK Breaks New Ground With First Government-Backed Psilocybin Therapy For Opioid Crisis

Newpark Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NR#NYSE">NR</a>) reported quarterly sales of $44.207 million which missed the analyst consensus estimate of $54.190 million by 18.42 percent. This is a 22.80 percent decrease over sales of $57.262 million the same period last year.

Newpark Resources Q3 Sales $44.207M Miss $54.190M Estimate

Grindr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRND#NYSE">GRND</a>) .

GRND

Grindr Raising FY 2024 Guidance to 29% or Greater Revenue Growth

ABNB

Airbnb shares are trading lower after the company reported worse-than-expected Q3 financial results and issued Q4 revenue guidance below estimates.

ClearPoint Neuro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLPT#NASDAQ">CLPT</a>) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.17) by 5.88 percent. This is a 10 percent increase over losses of $(0.20) per share from the same period last year. The company reported quarterly sales of $8.122 million which beat the analyst consensus estimate of $7.780 million by 4.40 percent. This is a 40.96 percent increase over sales of $5.762 million the same period last year.

CLPT

ClearPoint Neuro Q3 2024 GAAP EPS $(0.18) Misses $(0.17) Estimate, Sales $8.122M Beat $7.780M Estimate

RCM Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCMT#NASDAQ">RCMT</a>) reported quarterly earnings of $0.44 per share which beat the analyst consensus estimate of $0.38 by 15.79 percent. This is a 12 percent decrease over earnings of $0.50 per share from the same period last year. The company reported quarterly sales of $60.365 million which missed the analyst consensus estimate of $60.445 million by 0.13 percent. This is a 3.99 percent increase over sales of $58.049 million the same period last year.

RCMT

RCM Technologies Q3 2024 Adj. EPS $0.44 Beats $0.38 Estimate, Sales $60.365M Miss $60.445M Estimate

Nephros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEPH#NASDAQ">NEPH</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.02) by 200 percent. The company reported quarterly sales of $3.500 million which beat the analyst consensus estimate of $3.499 million by 0.03 percent. This is a 6.47 percent decrease over sales of $3.742 million the same period last year.

NEPH

Nephros Q3 2024 GAAP EPS $0.02 Beats $(0.02) Estimate, Sales $3.500M Beat $3.499M Estimate

Bitcoin briefly hit a fresh all-time high of $76,872 on Thursday before retreating, with financial markets continuing their rally in the wake of Donald Trump winning a <a href="https://www.benzinga.com/news/large-cap/24/11/41826586/wall-street-closes-at-record-highs-after-reassurance-from-powell-magnificent-7-hit-17-trillion-tre">second term in office</a>.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>&nbsp;$75,723.12</td>
<td>-0.3%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>&nbsp;$2,879.34&nbsp;</td>
<td>+7%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>&nbsp;$195.34</td>
<td>+3.4%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.1952</td>
<td>-3.1%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.00001896</td>
<td>-0.4%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul>
<li>IntoTheBlock data shows large transaction volume increasing by 83% and daily active addresses rising by 17%. </li>
<li>Coinglass data reports 102,336 traders were liquidated in the past 24 hours for $320 million, $200 million of which were liquidated short positions. </li>
</ul>
Notable Developments:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41807557/bitcoin-as-americas-gold-trumps-bitcoin-act-could-reshape-us-reserves-says-coinshares">Bitcoin As America&#8217;s Gold? How Trump&#8217;s Bitcoin Act Could Reshape US Reserves</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41819799/polymarket-ceo-on-election-night-it-looked-like-a-done-deal-on-platform-but-just-watching-">Polymarket CEO On Election Night: &#8216;It Looked Like A Done Deal&#8217; On Platform, But Just Watching TV &#8216;You Would Think It&#8217;s Neck And Neck&#8217;</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41818982/will-microstrategys-42-billion-bitcoin-bet-boost-mstr-stock-further">Will MicroStrategy&#8217;s $42 Billion Bitcoin Bet Boost MSTR Stock Further?</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41814313/dogwifhat-struggles-to-keep-up-with-dogecoin-shiba-inu-what-is-going-on">Dogwifhat Struggles To Keep Up With Dogecoin, Shiba Inu: What Is Going On?</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41823388/the-trump-effect-a-deep-dive-into-how-the-crypto-landscape-will-change-in-2025-and-beyond">The Trump Effect: A Deep Dive Into How The Crypto Landscape Will Change In 2025 And Beyond</a></li>
</ul>
Top Gainers:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Maker DAO (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/mkr/usd">MKR</a>)</td>
<td>&nbsp;$1,562</td>
<td>+17.5%</td>
</tr>
<tr>
<td>Ethena (CRYPTO: ENA)</td>
<td>&nbsp;$0.508</td>
<td>+12.8%</td>
</tr>
<tr>
<td>Cardano (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ada/usd">ADA</a>)</td>
<td>&nbsp;$0.4017</td>
<td>+11.5%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Trader Smileycapital <a href="https://x.com/smileycapital/status/1854635968659132728">cautioned</a> that &#8220;less is more&#8221; and predicts a &#8220;wealth effect&#8221; from increasing valuations in Bitcoin, Ethereum and Solana to trickle down to small-cap cryptocurrencies.
Analyst Ali Martinez expects the start of an altseason soon:
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Altseason hasn't even begun! We're in that part of the cycle where <a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> is still outpacing <a href="https://twitter.com/hashtag/Ethereum?src=hash&amp;ref_src=twsrc%5Etfw">#Ethereum</a>—totally normal at this stage. This could be the ideal time to stack up on altcoins, as history shows that altseason often follows shortly after. <a href="https://t.co/jxANVYk8kt">pic.twitter.com/jxANVYk8kt</a>
&mdash; Ali (@ali_charts) <a href="https://twitter.com/ali_charts/status/1854623178523328901?ref_src=twsrc%5Etfw">November 7, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Veteran analyst Benjamin Cowen pointed out that Bitcoin is following a familiar pattern to previous bull market cycles:
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/BTC?src=hash&amp;ref_src=twsrc%5Etfw">#BTC</a> still just doing what it always does at this point in the market cycle <a href="https://t.co/jK6F631PuG">pic.twitter.com/jK6F631PuG</a>
&mdash; Benjamin Cowen (@intocryptoverse) <a href="https://twitter.com/intocryptoverse/status/1854619730880889182?ref_src=twsrc%5Etfw">November 7, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
What&#8217;s Next: The influence of&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a>&nbsp;is expected to be thoroughly explored at Benzinga&#8217;s upcoming&nbsp;<a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a>&nbsp;event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41783773/the-future-of-crypto-regulation-under-a-trump-administration-headwinds-are-now-tailwinds">The Future Of Crypto Regulation Under A Trump Administration: &#8216;Headwinds Are Now Tailwinds&#8217;</a></li>
</ul>
Image: Shutterstock.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Topics

Markets

Movers

$ADA

$BTC

$DOGE

$ENA

$ETH

$MKR

$SHIB

$SOL

Bitcoin Hits Fresh All-Time High, Ethereum Rallies: 'Altseason Hasn't Even Begun,' Trader Says

Editors Note: This story has been updated to include a response from a Rocket Lab USA spokesperson and to correct the spelling of the company&#8217;s name in the headline. 
The social media account of&nbsp;Peter Beck, CEO of&nbsp;Rocket Lab USA Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>), was hacked, leading to a fraudulent post about a new crypto-based token.
What Happened: On Wednesday, the unauthorized post from Beck&#8217;s X, formerly Twitter account, promoted a new Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)-based token to fund space-related projects, reported Reuters.
<figure class="wp-block-image size-large"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06202850/Screenshot-2024-11-07-at-6.54.15%E2%80%AFAM-935x1024.png" alt="" class="wp-image-634096" /><figcaption class="wp-element-caption">Screenshot from Peter Back&#8217;s compromised X Account</figcaption></figure>
At the time of writing, the above post from Back&#8217;s account was removed.
See Also:&nbsp;<a href="https://www.benzinga.com/news/24/11/41702294/apple-begins-shifting-iphone-17-production-in-india-cooks-china-optimism-and-more-this-week-in-apple?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Apple Begins Shifting iPhone 17 Production In India, Cook&#8217;s China Optimism, And More: This Week In Appleverse</a>
A major player in the small satellite launch market valued at $6.5 billion, Rocket Lab was working with the platform to regain control of the account.&nbsp;
&#8220;Peter&#8217;s account has been compromised,&nbsp;so this is not an&nbsp;official tweet. We are working&nbsp;with X to restore it,&#8221;&nbsp;a company spokesperson confirmed in an email to Reuters.
Rocket Lab responded to Benzinga&#8217;s email updating about the account&#8217;s restoration. The company&#8217;s CEO also took to X, to share this information.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Account restored, thanks <a href="https://twitter.com/elonmusk?ref_src=twsrc%5Etfw">@elonmusk</a> and the X team for such a speedy fix! <a href="https://t.co/aOYIgeZ7Cd">https://t.co/aOYIgeZ7Cd</a>
&mdash; Peter Beck (@Peter_J_Beck) <a href="https://twitter.com/Peter_J_Beck/status/1854342132099961311?ref_src=twsrc%5Etfw">November 7, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: On Tuesday, Rocket Lab announced the successful launch of its <a href="https://www.benzinga.com/news/24/11/41750137/whats-going-on-with-rocket-lab-stock-tuesday">54th Electron mission</a>, deploying a single satellite to Low Earth Orbit for a confidential commercial customer.
Last month, Rocket Lab&#8217;s shares saw a boost following the Joe Biden administration&#8217;s <a href="https://www.benzinga.com/government/24/10/41392734/rocket-lab-stock-climbs-as-biden-administration-plans-to-ease-export-restrictions-on-space-companies">plans to ease export restrictions</a> on U.S. commercial space companies.
Check out more of Benzinga&#8217;s Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41706934/how-to-master-ios-18s-control-center-tips-to-reset-and-customize-your-iphones-quick-access-hub?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">How To Master iOS 18&#8217;s Control Center: Tips To Reset And Customize Your iPhone&#8217;s Quick Access Hub</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

Tech

Media

RKLB

Rocket Lab CEO Thanks Elon Musk And X Team For Speedy Restoration Of Hacked Account: 'Such A Speedy Fix!' (Updated)

Sight Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGHT#NASDAQ">SGHT</a>) affirms FY2024 sales outlook from $81.00 million-83.00 million to $81.00 million-83.00 million.

SGHT

Sight Sciences Affirms FY2024 Sales Guidance from $81.00M-83.00M to $81.00M-83.00M

ATA Creativity Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AACG#NASDAQ">AACG</a>) reported quarterly losses of $(0.06) per share. This is a 200 percent decrease over losses of $(0.02) per share from the same period last year. The company reported $9.58 million in sales this quarter. This is a 17.62 percent increase over sales of $8.15 million the same period last year.

Comments

Revelation Biosciences

Revelation Biosciences (REVBW) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO